SynthesisNeurosurgical review2026
Surgical outcomes and prognostic factors in epilepsy associated with low-grade brain tumors: a systematic review.
Synthesis in Neurosurgical review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Low-grade brain tumors such as gangliogliomas (GGs) and dysembryoplastic neuroepithelial tumors (DNETs) are common causes of drug-resistant epilepsy, particularly in children and young adults. While surgery is widely used to achieve seizure control, the degree of benefit and prognostic factors remain variably reported across the literature. To systematically evaluate seizure outcomes, extent of resection, and recurrence rates in patients undergoing epilepsy surgery for low-grade brain tumors. We conducted a systematic review of PubMed, Scopus, and Web of Science, following PRISMA 2020 guidelines. Sixty-seven studies involving 4,314 patients met inclusion criteria. Detailed characteristics of all included studies, including outcome definitions, follow-up duration, and key confounders, are provided in Table 2. Data on tumor type, extent of resection, seizure outcomes using Engel or International League Against Epilepsy (ILAE) classifications, recurrence, and complications were extracted. Risk of bias was assessed using the Newcastle–Ottawa Scale. Seizure freedom (Engel Class I or ILAE 1) was frequently reported, with rates often exceeding 70% across studies, with representative cohorts reporting rates of 215/287 at 60 months, 48/51 at a mean 44.2 months, and 20/26 at a mean 49.7 months. Gross total resection (GTR) was often associated with higher reported seizure freedom compared to subtotal resection, although stratified denominators were inconsistently reported across studies. GGs and DNETs showed the most favorable outcomes. Tumor recurrence was infrequently reported, particularly in patients with GTR. Postoperative morbidity was low, with only isolated cases of transient neurological deficits. Epilepsy surgery outcomes are particularly favorable for GGs and DNETs, especially when Gross Total Resection is achieved. Early intervention is associated with better outcomes, and surgery should be considered an early therapeutic option in appropriately selected patients with drug-resistant epilepsy and circumscribed lesions. Standardized reporting and prospective studies are needed to optimize surgical strategies and long-term care.
Indexed as
Identifiers
41680353What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.